<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1103210598
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Milrinone BOS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MILRINONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        786.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gland Pharma Limited " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gland Pharma Limited 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C01CE02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Milrinone, the active ingredient of the product, belongs to a group of medicines called phosphodiesterase inhibitors. It works by making your heart muscle contract more strongly and your blood vessels become wider. This means blood can flow more easily making your heart pump blood more successfully.</p><p>Milrinone TBM can be used for:<br />Short-term treatment of severe congestive heart failure (where the heart cannot pump enough blood to the rest of the body).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Milrinone TBM should not be given to you </strong><strong>if you:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are allergic to the active substance (milrinone) or any of the other ingredients of this medicine (listed in section 6). Signs of an allergic reaction include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have lost body fluids and are severely dehydrated.</p><p>If you are not sure, talk to your doctor, nurse or pharmacist before having Milrinone TBM</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, nurse or pharmacist before you are given this medicine if you:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are having or have just had a heart attack</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have severe heart valve problems such as narrowing, thickening, or blockage of your heart valve</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have uneven or uncontrolled fast heartbeats. You may also be experiencing pounding in your chest, light-headedness, fainting and shortness in breath</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have low blood pressure which may make you feel dizzy, light-headed or faint</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have previously taken water tablets (diuretics) which caused you to have heart problems</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have low levels of potassium in your blood. Your doctor may do blood tests to check this</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney problems</p><p>If you are not sure if any of the above apply to you, talk to your doctor, nurse or pharmacist before having Milrinone TBM.</p><p>&nbsp;</p><p><strong>Other medicines and Milrinone TBM</strong></p><p>Please tell your doctor, nurse or pharmacist if you are taking, have recently taken, or might take any other medicines. This includes prescription as well as non-prescription medication.</p><p>This is because milrinone can affect the way some other medicines work. Also some medicines can affect the way milrinone works. In particular, tell your doctor, nurse or pharmacist if you are taking:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; digoxin (used for heart problems)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; water tablets (diuretics)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat high blood pressure or angina (chest pain) such as amlodipine, nifedipine or felodipine.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, or pharmacist for advice before taking this medicine.</p><p>If you are breast-feeding or planning to breast-feed, talk to your doctor or pharmacist before taking any medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Milrinone TBM will always be given by your doctor or nurse. This is because it needs to be given as an injection. It is administered into a vein.</p><p>&nbsp;</p><p><strong>Having this medicine</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine is usually given in a &lsquo;drip&rsquo; after being diluted using either a sugar or salt solution.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you feel the effect of your medicine is too weak or too strong, tell your doctor or nurse.</p><p>&nbsp;</p><p><strong>How much will be given to you</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will decide how much medicine you should have based on your body weight.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have problems with your kidneys, you may be given a lower dose.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor should give you a first dose of 50 micrograms for every kilogram of your weight over 10 minutes.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This is then followed by a smaller dose between 0.375 and 0.75 micrograms for every kilogram of body weight per minute as needed.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The medicine is usually given for 2 to 3 days, but it may be given for up to 5 days.</p><p>&nbsp;</p><p>During infusion, you will be closely monitored. Your doctor will check a lot of parameters such as heart rhythm and blood pressure and blood will be taken to evaluate the response to therapy and occurrence of side effects.</p><p>&nbsp;</p><p><strong>If you take more Milrinone TBM than you should</strong></p><p>It is unlikely that your doctor or nurse will give you too much of his medicine. Your doctor and nurse will check your progress and the medicine that you are given. Always ask if you are not sure why you are getting a dose of medicine. The following effects may happen if you have too much Milrinone TBM: feeling dizzy, light-headedness and fainting (due to low blood pressure) and an uneven heartbeat.</p><p>&nbsp;</p><p><strong>If you have missed a dose of Milrinone TBM:</strong></p><p>Your doctor or nurse will have instructions on when to give you this medicine. It is unlikely that you will not be given the medicine as it has been prescribed. However, if you do think you have missed a dose, tell your doctor or nurse.</p><p>&nbsp;</p><p><strong>If you stop having Milrinone TBM</strong></p><p>Keep having this medicine until your doctor tells you to stop. Do not stop having this medicine just because you feel better. If you stop, your illness may get worse.</p><p>&nbsp;</p><p><strong>Tests</strong></p><p>Your doctor or nurse will use an electrocardiogram (ECG) to check how well your heart works. They will also carry out blood tests and check your blood pressure and pulse rate.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Stop having Milrinone TBM and tell you doctor straight away if </strong>you have an <strong>allergic reaction</strong>. The signs may include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue, fainting or losing consciousness. The chances of this happening are very rare.</p><p>&nbsp;</p><p><strong>Tell a doctor or nurse straight away if you notice any of the following side effects:</strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Common </em></strong><strong>(affects less than 1 in 10 people)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uneven, increased or fast heartbeats. You may also experience pounding in your chest, feel light-headed, faint or short of breath</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>Uncommon (affects less than 1 in 100 people)</em></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ventricular fibrillation &ndash; a serious heart rhythm problem. Signs of this include very fast, uneven or forceful heartbeat (palpitations), dizziness and loss of consciousness. You may also feel sick, have cold sweats, shortness of breath and chest pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombocytopenia &ndash; a blood problem. Signs of this are that you may bruise more easily than usual</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain</p><p>&nbsp;</p><p><strong><em>Very rare </em></strong><strong>(affects less than 1 in 10,000 people)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Torsades de Pointes</em> &ndash; a serious heart rhythm problem. Signs of this include very fast, uneven or forceful heartbeat (palpitations), dizziness and loss of consciousness. You may also feel sick, have cold sweats, shortness of breath, unusual pale complexion and chest pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty breathing, wheezing or tightness in the chest</p><p>&nbsp;</p><p><strong>Tell a doctor or nurse as soon as possible if you notice any of the following side effects:</strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Common </em></strong><strong>(affects less than 1 in 10 people)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure. Signs of this include feeling dizzy, lightheaded or fainting. If you also notice signs like a fast or uneven heartbeat or chest pain this could be a more serious side effect (see above)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&nbsp;</p><p><strong><em>Uncommon</em></strong><strong> (affects less than 1 in 100 people)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling shaky</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low levels of potassium in your blood. Signs of this are tiredness, confusion, muscle weakness and muscle cramps. This may be due to low levels of potassium in your body.</p><p>&nbsp;</p><p><strong>Tell a doctor or nurse if any of the following side effects gets serious or lasts longer than a few days</strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Very Rare</em></strong><strong> (affects less than 1 in 10,000 people)</strong></p><p>&bull; Skin rashes including at the site of the injection</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Uncommon </em></strong><strong>(affects less than 1 in 100 people)</strong></p><p>&bull; A blood test may show changes in the way the liver is working</p><p>&nbsp;</p><p>&nbsp;</p><p>Talk to your doctor, nurse or pharmacist if any of the side effects gets serious or lasts longer than a few days, or if you notice any side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shelf life of this product is 24&nbsp;months. Do not use this medicine after the expiry date which is stated on the carton and the blister pack. The expiry date refers to the last day of that month.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active ingredient of this product is milrinone.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: dextrose anhydrous, lactic acid, sodium hydroxide, and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Milrinone TBM is a clear and colourless to pale yellow solution containing 1 mg of Milrinone USP per mL. The product is filled as 10 mg in 10 mL USP Type I clear glass vial, stoppered with 20 mm bromobutyl rubber stoppers and sealed with 20 mm aluminium flip off seals.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tadawi Biomedical Company,</p><p>Sudair Industrial Zone,</p><p>Sudair,</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                08/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">المادة الفعالة لهذا المُنتج هي ميلرينون، وهي تنتمي إلى مجموعة الأدوية التي تُسمى مثبطات إنزيم الفوسفودي إستيراز. إنها تعمل على جعل عضلة القلب تنقبض بقوة أكبر وتصبح الأوعية الدموية أوسع. ويعني هذا أن الدم يمكن أن يتدفق بسهولة أكبر مما يجعل قلبك يضخ الدم بنجاح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن استخدام <strong>ميلرينون تي بي إم</strong> لأجل:</p><p dir="RTL">فترة علاج قصيرة الأمد لفشل القلب الاحتقاني الشديد (حيث لا يمكن للقلب ضخ ما يكفي من الدم لبقية الجسم).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا ينبغي إعطاء ميلرينون تي بي إم لكَ إذا كنت:</strong></p><p dir="RTL">&bull; تتحسس تجاه المادة الفعالة (ميلرينون) أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6). تشمل علامات رد الفعل التحسسي: طفح جلدي، مشاكل في البلع أو التنفس، تورم في شفتيك، وجهك، حلقك أو لسانك.</p><p dir="RTL">&bull; قد فقدت سوائل الجسم وتعاني من جفاف شديد.</p><p dir="RTL">إذا لم تكن متأكداً، تحدث إلى طبيبك، الممرضة أو الصيدلي قبل تناول <strong>ميلرينون تي بي إم</strong>.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المحاذير والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك، الممرضة أو الصيدلي قبل إعطائك هذا الدواء إذا كنت:</p><p dir="RTL">&bull; قد أُصبتَ أو حدثت لك نوبة قلبية للتو.</p><p dir="RTL">&bull; تعاني من مشاكل حادة في صمام القلب مثل تضيُّق، تضخُّم، أو انسداد في صمام قلبك.</p><p dir="RTL">&bull; تعاني من عدم انتظام ضربات القلب السريعة أو عدم التحكم فيها. قد تكون أيضاً تعاني من خفقان في صدرك، دُوار خفيف، إغماء وضيق في التنفس.</p><p dir="RTL">&bull; تعاني من انخفاض ضغط الدم مما قد يجعلك تشعر بدوخة، أو الدوخة، أو إغماء.</p><p dir="RTL">&bull; قد تناولت من قبل أقراص الماء (مدرات البول) التي سبَّبت لك مشاكل في القلب.</p><p dir="RTL">&bull; قد عانيت من انخفاض مستويات البوتاسيوم في دمك. قد يقوم طبيبك بإجراء فحوصات دم للتحقق من ذلك.</p><p dir="RTL">&bull; قد عانيت من مشاكل في الكلى.</p><p dir="RTL">إذا لم تكن متأكداً فيما إذا كان أيّاً مما سبق ينطبق عليك، تحدث إلى طبيبك، الممرضة أو الصيدلي قبل تناول <strong>ميلرينون تي بي إم</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية أخرى وميلرينون تي بي إم</strong></p><p dir="RTL">يرجى إخبار طبيبك، الممرضة أو الصيدلي فيما إذا كنت تأخذ، أو قد أخذت مؤخراً، أو قد تأخذ أية أدوية أخرى. ويشمل ذلك أدوية الوصفة الطبية والأدوية التي بدون وصفة طبية.</p><p dir="RTL">وهذا لأن ميلرينون يمكن أن يؤثر على طريقة عمل بعض الأدوية الأخرى. وأيضاً بعض الأدوية يمكن أن تؤثر على طريقة عمل ميلرينون. وبخاصة، أخبر طبيبك، الممرضة أو الصيدلي إذا كنت تأخذ:</p><p dir="RTL">&bull; ديجوكسين (المستخدم لمشاكل القلب).</p><p dir="RTL">&bull; أقراص الماء (مدرات البول).</p><p dir="RTL">&bull; أدوية مستخدمة لعلاج ارتفاع ضغط الدم أو الذبحة الصدرية (ألم الصدر) مثل أملوديبين، نيفيديبين أو فيلوديبين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو مرضعةً، تعتقدين أنكِ قد تكوني حاملاً أو تخططينَ لإنجاب طفل، اسألي طبيبك، أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL">إذا كنتِ ترضعينَ طفلكِ أو تخططينَ للرضاعة الطبيعية، تحدثي مع طبيبكِ أو الصيدلي قبل تناول أي دواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم إعطاء <strong>ميلرينون تي بي إم </strong>دائماً من قبل طبيبك أو ممرضتك. لأن هذا الدواء يحتاج للإعطاء بواسطة حقنة. ويوصى بحقنها في الوريد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناول هذا الدواء</strong></p><p dir="RTL">&bull; يُعطى هذا الدواء عادةً &quot;بالتسريب&quot; بعد تخفيفه باستخدام محلول سكري أو ملحي.</p><p dir="RTL">&bull; إذا شعرت بأن تأثير دواؤك ضعيفٌ جداً أو قويٌّ جداً، أخبر طبيبك أو ممرضتك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما الكمية التي ستُعطى لك</strong></p><p dir="RTL">&bull; سيقرر طبيبك مقدار الدواء الذي يجب أن تتناوله استناداً إلى وزن جسمك.</p><p dir="RTL">&bull; إذا كنت تعاني من مشاكل في كليتيك، فقد تُعطى جرعة أقل.</p><p dir="RTL">&bull; يجب أن يعطيك طبيبك الجرعة الأولى البالغة 50 مكغ لكل كيلوغرام من وزنك على مدى 10 دقائق.</p><p dir="RTL">&bull; وهذه تتبعها بعد ذلك جرعة أصغر ما بين 0،375 و0،75 مكغ لكل كيلوغرام من وزن الجسم في الدقيقة الواحدة حسب الحاجة.</p><p dir="RTL">&bull; يُعطى الدواء عادةً لمدة 2 إلى 3 أيام، ولكن يمكن إعطاءه لمدة تصل حتى 5 أيام.</p><p dir="RTL">أثناء التسريب، ستكونُ تحت المراقبة عن كثب. سيتحقق طبيبك من عددٍ من العوامل مثل إيقاع القلب وضغط الدم وسيؤخذ الدم لتقييم الاستجابة للمعالجة وحدوث التأثيرات الجانبية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا أخذتَ ميلرينون تي بي إم أكثر مما يجب</strong></p><p dir="RTL">من غير المحتمل أن يُعطيك طبيبك أو ممرضتك الكثير من الدواء. سيتحقق طبيبك والممرضة من تقدمك ومن الدواء الذي يُعطى لك. اسأل دائماً إذا كنت غير متأكد عن سبب حصولك على جرعة من الدواء. قد تحدث لديك التأثيرات التالية إذا أخذت الكثير من <strong>ميلرينون تي بي إم</strong>: شعور بدوخة، دوار خفيف وإغماء (بسبب انخفاض ضغط الدم) وحتى عدم انتظام ضربات القلب.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا فاتتك جرعة من ميلرينون تي بي إم:</strong></p><p dir="RTL">لدى طبيبك أو ممرضتك التعليمات بموعد إعطائك هذا الدواء. فمن غير المحتمل أنك لم تُعطى الدواء كما هو موصوف لك. مع ذلك، إذا كنت تعتقد أنه قد فاتتك جرعة ما، أخبر طبيبك أو ممرضتك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا توقفت عن تناول ميلرينون تي بي إم</strong></p><p dir="RTL">استمر بتناول هذا الدواء حتى يخبرك طبيبك بالتوقف. لا تتوقف عن تناول هذا الدواء لمجرد أنك شعرت بتحسن. إذا توقفت، قد يتفاقم مرضك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>فحوصات</strong></p><p dir="RTL">سيستخدم طبيبك أو ممرضتك تخطيط القلب الكهربائي (ECG) للتحقق من كيفية عمل قلبك. وسيقومون أيضاً بإجراء فحوصات دم ويتحققون من ضغط الدم ومعدل النبض.</p><p dir="RTL">إذا كان لديك أية أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء تأثيرات جانبية، ولو أنها لا تحصل لدى كل شخص.</p><p dir="RTL"><strong>توقف عن تناول ميلرينون تي بي إم وأخبر طبيبك على الفور إذا حصل لديك رد فعل تحسسي</strong>. وهذه العلامات قد تشمل: طفح جلدي، مشاكل في البلع أو التنفس، تورم في شفتيك، وجهك، حلقك أو لسانك، إغماء أو فقدان الوعي. وفرص حدوث ذلك نادرة جداً.</p><p dir="RTL"><strong>أخبر الطبيب أو الممرضة على الفور إذا لاحظت أيّاً من التأثيرات الجانبية التالية:</strong></p><p dir="RTL"><strong><em>شائعة</em></strong><strong> (قد تؤثر في أقل من 1 من كل 10 أشخاص)</strong></p><p dir="RTL">&bull; عدم انتظام، زيادة أو سرعة دقات القلب. قد تواجه أيضاً خفقان في صدرك، شعور بدوار، ضعفٌ أو ضيق تنفس.</p><p dir="RTL"><strong><em>غير شائعة</em></strong><strong> (قد تؤثر في أقل من 1 من كل 100 شخص)</strong></p><p dir="RTL">&bull; رجفان بطيني - مشكلة خطيرة في ضربات القلب. تشمل علامات ذلك على نبضات قلب سريعة جداً، غير متوازنة أو قوية (خفقان)، دوخة وفقدان وعي. وقد تشعر أيضاً بالغثيان، تعرُّق بارد، ضيق تنفس وألم في الصدر.</p><p dir="RTL">&bull; قلة الصفيحات - مشكلة في الدم. من علامات ذلك هي أنك قد تُصاب برضوضٍ بسهولة أكثر من المعتاد.</p><p dir="RTL">&bull; ألم في الصدر.</p><p dir="RTL"><strong><em>نادرة جداً</em></strong><strong> (قد تؤثر في أقل من 1 من كل 10000 شخص)</strong></p><p dir="RTL">&bull; Torsades de Pointes (TdP) نوع محدد من إيقاع القلب غير الطبيعي الذي يؤدي إلى الموت القلبي المفاجئ. تشمل علاماتها على نبضات قلب سريعة جداً، غير متوازنة أو قوية (خفقان)، دوخة وفقدان وعي. وقد تشعر أيضاً بكونك مريض، تعرُّق بارد، ضيق تنفس، مظهر شاحب غير طبيعي وألم في الصدر.</p><p dir="RTL">&bull; صعوبة في التنفس، صفير أو ضيق في الصدر.</p><p dir="RTL"><strong>أخبر الطبيب أو الممرضة بأسرع ما يمكن إذا لاحظت أيّاً من التأثيرات الجانبية التالية:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><em>شائعة</em></strong><strong> (قد تؤثر في أقل من 1 من كل 10 أشخاص)</strong></p><p dir="RTL">&bull; ضغط دم منخفض. علامات ذلك تشمل شعور بدوار، دوخة، أو إغماء. وإذا لاحظت أيضاً علامات مثل دقات قلب سريعة أو غير متوازنة أو ألم في الصدر، فقد يكون ذلك من التأثيرات الجانبية الأكثر خطورة (انظر أعلاه).</p><p dir="RTL">&bull; صداع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>غير شائعة</em></strong><strong> (قد تؤثر في أقل من 1 من كل 100 شخص)</strong></p><p dir="RTL">&bull; شعور برجفة.</p><p dir="RTL">&bull; انخفاض مستويات البوتاسيوم في دمك. علامات ذلك هي تعب، ارتباك، ضعف عضلات وتشنج عضلات. قد يكون ذلك بسبب انخفاض مستويات البوتاسيوم في جسمك.</p><p dir="RTL"><strong>أخبر الطبيب أو الممرضة إذا كان أيّاً من التأثيرات الجانبية التالية أصبح خطيراً أو استمر لفترة أطول من بضعة أيام.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>نادرة جداً</em></strong><strong> (قد تؤثر في أقل من 1 من كل 10،000 شخص)</strong></p><p dir="RTL">&bull; طفح جلدي يشمل مكان الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>غير شائعة</em></strong><strong> (قد تؤثر في أقل من 1 من كل 100 شخص)</strong></p><p dir="RTL">&bull; قد يُظهر فحص الدم تغيُّرات في طريقة عمل الكبد.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">تحدث إلى طبيبك، الممرضة أو الصيدلي إذا أصبح أيّاً من التأثيرات الجانبية خطيراً أو استمر لفترة أطول من بضعة أيام، أو إذا لاحظت أية تأثيرات جانبية غير مذكورة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; احفظ هذا الدواء بعيدًا عن رؤية ومتناول الأطفال.</p><p dir="RTL">&bull; مدة صلاحية هذا المنتج هي 24 شهراً. لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الكرتونة وعلى الشريط. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&bull; يحفظ بدرجة حرارة دون 30 مئوية. تجنب التجميد.</p><p dir="RTL">&bull; لا تتخلص من أية أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. هذه التدابير سوف تُساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; المادة الفعالة لهذا المنتج هي ميلرينون.</p><p dir="RTL">&bull; المكونات الأخرى هي: سكر العنب اللامائي، حامض اللبن، هيدروكسيد الصوديوم، وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ميلرينون تي بي إم</strong> هو محلول صافي عديم اللون إلى أصفر شاحب يحتوي على 1 ملغ من ميلرينون USP في كل 1 مل. والمنتج معبأ بنحو 10 ملغ في قارورة زجاجية سعة 10 مل ناصعة من النوع 1 وفق دستور الأدوية الأمريكي، ومغلقة بسدادات بروموبوتيل مطاطية قطر 20 مم مختومة بغطاء ألمنيوم قطر 20 مم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة تداوي الطبية الحيوية</p><p dir="RTL">تداوي الطبية الحيوية&nbsp;- المملكة العربية السعودية</p><p dir="RTL">الرياض، منطقة سُدير الصناعية،</p><p dir="RTL">المنطقة أ، شارع 11،</p><p dir="RTL">المصنع 107 - السعودية العربية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            08/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Milrinone TBM
Milrinone lactate Injection, 1 mg/mL, 10 mL vial
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 10 mL vial contains 10 mg of milrinone.
Excipient with known effect
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for Injection
Clear and colorless to pale yellow solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Milrinone TBM is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. Patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. The facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p>Milrinone TBM should be administered with a loading dose followed by a continuous infusion (maintenance dose) according to the following guidelines:</p><p><u>Loading Dose:</u></p><p>50 &micro;g/kg: Administer slowly over 10 minutes</p><p>The table below shows the loading dose in milliliters (mL) of milrinone (1 mg/mL) by patient body weight (kg).</p><p style="text-align:center">Loading Dose (mL) Using 1 mg/mL Concentration</p><table border="1" cellspacing="1" cellpadding="1" style="width:801px"><tbody><tr><td colspan="11" style="text-align:center; width:157px">Patient weight in kg</td></tr><tr><td style="text-align:center; width:49px">Kg</td><td style="text-align:center; width:47px">30</td><td style="text-align:center; width:52px">40</td><td style="text-align:center; width:46px">50</td><td style="text-align:center; width:50px">60</td><td style="text-align:center; width:53px">70</td><td style="text-align:center; width:50px">80</td><td style="text-align:center; width:50px">90</td><td style="text-align:center; width:53px">100</td><td style="text-align:center; width:53px">110</td><td style="text-align:center; width:296px">120</td></tr><tr><td style="text-align:center; width:49px">mL</td><td style="text-align:center; width:47px">1.5</td><td style="text-align:center; width:52px">2.0</td><td style="text-align:center; width:46px">2.5</td><td style="text-align:center; width:50px">3.0</td><td style="text-align:center; width:53px">3.5</td><td style="text-align:center; width:50px">4.0</td><td style="text-align:center; width:50px">4.5</td><td style="text-align:center; width:53px">5.0</td><td style="text-align:center; width:53px">5.5</td><td style="text-align:center; width:296px">6.0</td></tr></tbody></table><p>The loading dose may be given undiluted, but diluting to a rounded total volume of 10 mL or 20 mL (see Maintenance Dose for diluents) may simplify the visualisation of the injection rate.</p><p style="text-align:center">MAINTENANCE DOSE</p><table border="1" cellspacing="1" cellpadding="1" style="width:649px"><tbody><tr><td style="text-align:center; width:193px">&nbsp;</td><td style="text-align:center; width:147px">Infusion rate</td><td style="text-align:center; width:136px">Total Daily dose (24 hours)</td><td style="text-align:center; width:172px">&nbsp;</td></tr><tr><td style="text-align:center; width:193px">Minimum</td><td style="text-align:center; width:147px">0.375 &micro;g/kg/min</td><td style="text-align:center; width:136px">0.59 mg/kg</td><td rowspan="3" colspan="1" style="text-align:center; width:172px">Administer as continuous intravenous infusion</td></tr><tr><td style="text-align:center; width:193px">Standard</td><td style="text-align:center; width:147px">0.50 &micro;g/kg/min</td><td style="text-align:center; width:136px">0.77 mg/kg</td></tr><tr><td style="text-align:center; width:193px">Maximum</td><td style="text-align:center; width:147px">0.75 &micro;g/kg/min</td><td style="text-align:center; width:136px">1.13 mg/kg</td></tr></tbody></table><p>Milrinone drawn from vials should be diluted prior to maintenance dose administration. The diluents that may be used are 0.9% Sodium Chloride Injection or 5% Dextrose Injection.</p><p>The table below shows the volume of diluent in millilitres (mL) that must be used to achieve 200 &micro;g/mL concentrations for infusion, and the resultant total volumes.</p><table border="1" cellspacing="1" cellpadding="1" style="width:647px"><tbody><tr><td style="text-align:center; width:143px">Desired Infusion Concentration &micro;g/mL</td><td style="text-align:center; width:161px">Milrinone 1 mg/mL (mL)</td><td style="text-align:center; width:177px">Diluent (mL)</td><td style="text-align:center; width:164px">Total Volume (mL)</td></tr><tr><td style="text-align:center; width:143px">200</td><td style="text-align:center; width:161px">10</td><td style="text-align:center; width:177px">40</td><td style="text-align:center; width:164px">50</td></tr><tr><td style="text-align:center; width:143px">200</td><td style="text-align:center; width:161px">20</td><td style="text-align:center; width:177px">80</td><td style="text-align:center; width:164px">100</td></tr></tbody></table><p>The infusion rate should be adjusted according to hemodynamic and clinical response. Patients should be closely monitored. In controlled clinical studies, most patients showed an improvement in hemodynamic status as evidenced by increases in cardiac output and reductions in pulmonary capillary wedge pressure.</p><p>Note: See <strong>&quot;Dosage Adjustment in Renally Impaired Patients</strong>.&quot;</p><p>Dosage may be titrated to the maximum hemodynamic effect and should not exceed 1.13 mg/kg/day. Duration of therapy should depend upon patient responsiveness.</p><p><u>Maintenance Dose:</u></p><p>The maintenance dose in mL/hr by patient body weight (kg) may be determined by reference to the following table.</p><p style="text-align:center">Milrinone Infusion Rate (mL/hr) Using 200 mcg/mL Concentration</p><table border="1" cellspacing="1" cellpadding="1" style="width:653px"><tbody><tr><td rowspan="2" colspan="1" style="text-align:center; width:52px">Maintenance Dose (&micro;g/kg/min)</td><td rowspan="1" colspan="10" style="text-align:center; width:600px">Patient Body Weight (kg)</td></tr><tr><td style="text-align:center; width:55px">30</td><td style="text-align:center; width:48px">40</td><td style="text-align:center; width:68px">50</td><td style="text-align:center; width:62px">60</td><td style="text-align:center; width:65px">70</td><td style="text-align:center; width:63px">80</td><td style="text-align:center; width:62px">90</td><td style="text-align:center; width:63px">100</td><td style="text-align:center; width:57px">110</td><td style="text-align:center; width:52px">120</td></tr><tr><td style="text-align:center; width:52px">0.375</td><td style="text-align:center; width:55px">3.4</td><td style="text-align:center; width:48px">405</td><td style="text-align:center; width:68px">5.6</td><td style="text-align:center; width:62px">6.8</td><td style="text-align:center; width:65px">709</td><td style="text-align:center; width:63px">9.0</td><td style="text-align:center; width:62px">10.1</td><td style="text-align:center; width:63px">10.1</td><td style="text-align:center; width:57px">12.4</td><td style="text-align:center; width:52px">13.5</td></tr><tr><td style="text-align:center; width:52px">0.400</td><td style="text-align:center; width:55px">3.6</td><td style="text-align:center; width:48px">4.8</td><td style="text-align:center; width:68px">6.0</td><td style="text-align:center; width:62px">7.2</td><td style="text-align:center; width:65px">8.4</td><td style="text-align:center; width:63px">9.6</td><td style="text-align:center; width:62px">10.8</td><td style="text-align:center; width:63px">12.0</td><td style="text-align:center; width:57px">13.2</td><td style="text-align:center; width:52px">14.4</td></tr><tr><td style="text-align:center; width:52px">0.500</td><td style="text-align:center; width:55px">4.5</td><td style="text-align:center; width:48px">6.0</td><td style="text-align:center; width:68px">7.5</td><td style="text-align:center; width:62px">9.0</td><td style="text-align:center; width:65px">10.5</td><td style="text-align:center; width:63px">12.0</td><td style="text-align:center; width:62px">13.5</td><td style="text-align:center; width:63px">15.0</td><td style="text-align:center; width:57px">16.5</td><td style="text-align:center; width:52px">18.8</td></tr><tr><td style="text-align:center; width:52px">0.600</td><td style="text-align:center; width:55px">5.4</td><td style="text-align:center; width:48px">7.2</td><td style="text-align:center; width:68px">9.0</td><td style="text-align:center; width:62px">10.8</td><td style="text-align:center; width:65px">12.6</td><td style="text-align:center; width:63px">14.4</td><td style="text-align:center; width:62px">16.2</td><td style="text-align:center; width:63px">18.0</td><td style="text-align:center; width:57px">19.8</td><td style="text-align:center; width:52px">21.6</td></tr><tr><td style="text-align:center; width:52px">0.700</td><td style="text-align:center; width:55px">6.3</td><td style="text-align:center; width:48px">8.4</td><td style="text-align:center; width:68px">10.5</td><td style="text-align:center; width:62px">12.6</td><td style="text-align:center; width:65px">14.7</td><td style="text-align:center; width:63px">16.8</td><td style="text-align:center; width:62px">18.9</td><td style="text-align:center; width:63px">21.0</td><td style="text-align:center; width:57px">23.1</td><td style="text-align:center; width:52px">25.2</td></tr><tr><td style="text-align:center; width:52px">0.750</td><td style="text-align:center; width:55px">6.8</td><td style="text-align:center; width:48px">9.0</td><td style="text-align:center; width:68px">11.3</td><td style="text-align:center; width:62px">13.5</td><td style="text-align:center; width:65px">15.8</td><td style="text-align:center; width:63px">18.0</td><td style="text-align:center; width:62px">20.3</td><td style="text-align:center; width:63px">22.5</td><td style="text-align:center; width:57px">24.8</td><td style="text-align:center; width:52px">27.0</td></tr></tbody></table><p>When administering milrinone lactate by continuous infusion, it is advisable to use a calibrated electronic infusion device.</p><p><strong>Dosage Adjustments in Adult Patients with Renal Impairment</strong></p><p>Data obtained from patients with severe renal impairment (creatinine clearance = 0 to 30 mL/min) but without congestive heart failure have demonstrated that the presence of renal impairment significantly increases the terminal elimination half-life of milrinone. Reductions in infusion rate may be necessary in patients with renal impairment. For patients with clinical evidence of renal impairment, the recommended infusion rate can be obtained from the following table:</p><table border="1" cellspacing="1" cellpadding="1" style="width:655px"><tbody><tr><td style="text-align:center; width:302px">Creatinine Clearance (mL/min/1.73m2 )</td><td style="text-align:center; width:349px">Infusion Rate (&micro;g/kg/min)</td></tr><tr><td style="text-align:center; width:302px">5</td><td style="text-align:center; width:349px">0.20</td></tr><tr><td style="text-align:center; width:302px">10</td><td style="text-align:center; width:349px">0.23</td></tr><tr><td style="text-align:center; width:302px">20</td><td style="text-align:center; width:349px">0.28</td></tr><tr><td style="text-align:center; width:302px">30</td><td style="text-align:center; width:349px">0.33</td></tr><tr><td style="text-align:center; width:302px">40</td><td style="text-align:center; width:349px">0.38</td></tr><tr><td style="text-align:center; width:302px">50</td><td style="text-align:center; width:349px">0.43</td></tr></tbody></table><p>Intravenous drug products should be inspected visually and should not be used if particulate matter or discoloration is present.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Milrinone TBM is contraindicated in patients with a hypersensitivity to the active substance, milrinone, or to any of the excipients listed in section 6.1. 
Milrinone TBM is also contraindicated in patients with severe hypovolemia.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Warning</strong></u></p><p>Whether given orally or by continuous or intermittent intravenous infusion, milrinone has not been shown to be safe or effective in the longer (greater than 48 hours) treatment of patients with heart failure. In a multicentre trial of 1088 patients with Class III and IV heart&nbsp;failure, long-term oral treatment with milrinone was associated with no improvement in symptoms and an increased risk of hospitalisation and death. In this study, patients with Class IV symptoms appeared to be at particular risk of life-threatening cardiovascular reactions. There is no evidence that milrinone given by long-term continuous or intermittent infusion does not carry a similar risk. The use of milrinone both intravenously and orally has been associated with increased frequency of ventricular arrhythmias, including non-sustained ventricular tachycardia. Long-term oral use has been associated with an increased risk of sudden death. Hence, patients receiving milrinone should be observed closely with the use of continuous electrocardiographic monitoring to allow the prompt detection and management of ventricular arrhythmias.</p><p><u><strong>Precautions</strong></u></p><p><em>General</em></p><p>Milrinone should not be used in patients with severe obstructive aortic or pulmonic valvular disease in lieu of surgical relief of the obstruction. Like other inotropic agents, it may aggravate outflow tract obstruction in hypertrophic subaortic stenosis. Supraventricular and ventricular arrhythmias have been observed in the high-risk population treated with milrinone. In some patients, injections of milrinone and oral milrinone have been shown to increase ventricular ectopy, including non-sustained ventricular tachycardia. The potential for arrhythmia, present in congestive heart failure itself, may be increased by many drugs or combinations of drugs. Patients receiving milrinone should be closely monitored during infusion. Milrinone produces a slight shortening of AV node conduction time, indicating a potential for an increased ventricular response rate in patients with atrial flutter/fibrillation which is not controlled with digitalis therapy. During therapy with milrinone, blood pressure and heart rate should be monitored and the rate of infusion slowed or stopped in patients showing excessive decreases in blood pressure. If prior vigorous diuretic therapy is suspected to have caused significant decreases in cardiac filling pressure, milrinone should be cautiously administered with monitoring of blood pressure, heart rate, and clinical symptomatology. There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. Cases of infusion site reactions have been reported with intravenous milrinone&nbsp;therapy. (see section 4.8) Consequently,<strong> careful monitoring of the infusion site should be maintained </strong>to avoid possible extravasation.</p><p><em>Use in Acute Myocardial Infarction</em></p><p>The use of inotropic agents such as milrinone during the acute phase of a myocardial infarction may lead to an undesirable increase in myocardial oxygen consumption (MVO2). No clinical studies have been conducted in patients in the acute phase of post myocardial infarction. Until further clinical experience with this class of drugs is gained, milrinone is not recommended in these patients.</p><p><em>Laboratory Tests</em></p><p>Fluid and Electrolytes: Fluid and electrolyte changes and renal function should be carefully monitored during therapy with milrinone. Improvement in cardiac output with resultant diuresis may necessitate a reduction in the dose of diuretic. Potassium loss due to excessive diuresis may predispose digitalized patients to arrhythmias. Therefore, hypokalaemia should be corrected by potassium supplementation in advance of or during use of milrinone.</p><p><em>Thrombocytopenia</em>: Decrease in haemoglobin, including anaemia, often takes place in the setting of cardiac failure. Due to the risk of thrombocytopenia or anaemia, careful monitoring of the corresponding laboratory parameters is required in patients with decreased platelet count or decreased haemoglobin</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Drug Interaction</p><p>No untoward clinical manifestations have been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerine; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements.</p><p>Chemical Interaction There is an immediate chemical interaction which is evidenced by the formation of a precipitate when furosemide is injected into an intravenous line of an infusion of milrinone.</p><p>Therefore, furosemide should not be administered in intravenous lines containing milrinone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Fertility</u></p><p>No impact on fertility was detected in animal studies (see section 5.3). No clinical data are available, potential risk for human is unknown</p><p><u>Pregnancy</u></p><p>Pregnancy Category C There are no adequate and well-controlled studies in pregnant women. Milrinone should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.</p><p><u>Lactation</u></p><p>Caution should be exercised when milrinone is administered to nursing women, since it is not known whether it is excreted in human milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effect on the ability to drive and use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Cardiovascular Effects:</em> In patients receiving milrinone in Phase II and III clinical trials, ventricular arrhythmias were reported in 12.1%: Ventricular ectopic activity, 8.5%; nonsustained ventricular tachycardia, 2.8%; sustained ventricular tachycardia, 1% and ventricular fibrillation, 0.2% (2 patients experienced more than one type of arrhythmia). Holter recordings demonstrated that in some patients injection of milrinone increased ventricular ectopy, including non-sustained ventricular tachycardia. Life-threatening arrhythmias were infrequent and when present have been associated with certain underlying factors such as pre-existing arrhythmias, metabolic abnormalities (e.g., hypokalaemia), abnormal digoxin levels and catheter insertion. Milrinone was not shown to be arrhythmogenic in an electrophysiology study. Supraventricular arrhythmias were reported in 3.8% of the patients receiving milrinone. The incidence of both supraventricular and ventricular arrhythmias has not been related to the dose or plasma milrinone concentration. Other cardiovascular adverse reactions include hypotension, 2.9% and angina/chest pain, 1.2%. In the post-marketing experience, there have been rare cases of &ldquo;torsades de pointes&rdquo; reported.</p><p><em>CNS Effects:</em> Headaches, usually mild to moderate in severity, have been reported in 2.9% of patients receiving milrinone.س</p><p><em>Other Effects&nbsp;</em></p><p>Other adverse reactions reported, but not definitely related to the administration of milrinone include hypokalaemia, 0.6%; tremor, 0.4%; and thrombocytopenia, 0.4%.</p><p>Post-Marketing Adverse Event Reports</p><p>In addition to adverse events reported from clinical trials, the following events have been reported from worldwide post-marketing experience with milrinone:</p><p>&bull; Isolated spontaneous reports of bronchospasm and anaphylactic shock.</p><p>&bull; Liver function test abnormalities and skin reactions such as rash.</p><p>&bull; Administration site conditions: Infusion site reaction.</p><p>Tabulated list of adverse reactions</p><p>Adverse reactions have been ranked under heading of system-organ class and frequency using the following convention: very common (&ge;1/10); common (&ge;1/100, &le;1/10); uncommon (&ge;1/1,000, &le;1/100); rare (&ge;1/10,000, &le;1/1,000); very rare (&le;1/10,000); not known (cannot be estimated from the available data).</p><table border="1" cellspacing="1" cellpadding="1" style="width:896px"><tbody><tr><td colspan="2" style="width:443px">Blood and the lymphatic system disorders:</td></tr><tr><td style="width:443px">Uncommon</td><td style="width:452px">Thrombocytopenia</td></tr><tr><td colspan="2" style="width:443px">Immune system disorders</td></tr><tr><td style="width:443px">Very rare</td><td style="width:452px">Anaphylactic shock</td></tr><tr><td colspan="2" style="width:443px">Metabolism and nutrition disorders</td></tr><tr><td style="width:443px">Uncommon</td><td style="width:452px">Hypokalaemia</td></tr><tr><td colspan="2" style="width:443px">Nervous system disorders</td></tr><tr><td style="width:443px">Common</td><td style="width:452px">Headaches</td></tr><tr><td style="width:443px">Uncommon</td><td style="width:452px">Tremor</td></tr><tr><td colspan="2" style="width:443px">Cardiac disorders</td></tr><tr><td style="width:443px">Common</td><td style="width:452px">Ventricular ectopic activity, Non sustained or sustained ventricular Tachycardia (see section 4.4), Supraventricular arrhythmias, Hypotension</td></tr><tr><td style="width:443px">Uncommon</td><td style="width:452px">Ventricular fibrillation, Angina/chest pain</td></tr><tr><td style="width:443px">Very rare</td><td style="width:452px">Torsades de pointes</td></tr><tr><td colspan="2" style="width:443px">Respiratory, thoracic and mediastinal disorders</td></tr><tr><td style="width:443px">Very rare</td><td style="width:452px">Bronchospasm</td></tr><tr><td colspan="2" style="width:443px">Hepato-biliary disorders</td></tr><tr><td style="width:443px">Hepato-biliary disorders</td><td style="width:452px">Liver function tests abnormal</td></tr><tr><td colspan="2" style="width:443px">Skin and subcutaneous tissue disorders</td></tr><tr><td style="width:443px">Very rare</td><td style="width:452px">rash</td></tr><tr><td colspan="2" style="width:443px">Renal and urinary disorders</td></tr><tr><td style="width:443px">Not known</td><td style="width:452px">Renal failure, secondary to a concomitant hypotension</td></tr><tr><td colspan="2" style="width:443px">General disorders and administration site conditions</td></tr><tr><td style="width:443px">Not known</td><td style="width:452px">Infusion site reaction</td></tr></tbody></table><p><em>Paediatric</em></p><p>Use Safety and effectiveness in paediatric patients have not been established.</p><p><em>Geriatric</em></p><p>Use There are no special dosage recommendations for the elderly patient. Ninety percent of all patients administered milrinone in clinical studies were within the age range of 45 to 70 years, with a mean age of 61 years. Patients in all age groups demonstrated clinically and statistically significant responses. No age-related effects on the incidence of adverse reactions have been observed. Controlled pharmacokinetic studies have not disclosed any age-related effects on the distribution and elimination of milrinone.</p><p><strong>To reports any side effect(s):</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to the competent authority in Saudi Arabia as per details below:</p><p>To report any side effect(s):</p><ul><li><strong>Saudi Arabia</strong></li></ul><p>The National Pharmacovigilance and Drug Safety Centre (NPC) - Fax: +966-11-205-7662<br />- Call NPC at +966-11-2038222, Ext 2317-2356-2340<br />- SFDA Call Center: 19999<br />-&nbsp;E-mail:&nbsp;npc.drug@sfda.gov.sa<br />- Website:&nbsp;https://ade.sfda.gov.sa/</p><ul><li><strong>&nbsp;Other GCC States:</strong></li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doses of milrinone may produce hypotension because of its vasodilator effect. If this occurs, administration of milrinone should be reduced or temporarily discontinued until the patient&#39;s condition stabilises. No specific antidote is known, but general measures for circulatory support should be taken</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Cardiac therapy; Phosphodiesterase inhibitor, ATC code: C01CE02<br />Milrinone is a positive inotrope and vasodilator, with little chronotropic activity different in structure and mode of action from either the digitalis glycosides or catecholamines. Milrinone, at relevant inotropic and vasorelaxant concentrations, is a selective inhibitor of peak III cAMP phosphodiesterase isozyme in cardiac and vascular muscle. This inhibitory action is consistent with cAMP mediated increases in intracellular ionized calcium and contractile force in cardiac muscle, as well as with cAMP dependent contractile protein phosphorylation and relaxation in vascular muscle. Additional experimental evidence also indicates that milrinone is not a beta-adrenergic agonist nor does it inhibit sodium-potassium adenosine triphosphatase activity as do the digitalis glycosides.</p><p>Clinical studies in patients with congestive heart failure have shown that milrinone produces dose-related and plasma drug concentration-related increases in the maximum rate of increase of left ventricular pressure. Studies in normal subjects have shown that milrinone produces increases in the slope of the left ventricular pressure-dimension relationship, indicating a direct inotropic effect of the drug. Milrinone also produces dose- related and plasma concentration-related increases in forearm blood flow in patients with congestive heart failure, indicating a direct arterial vasodilator activity of the drug.</p><p>Both the inotropic and vasodilatory effects have been observed over the therapeutic range of plasma milrinone concentrations of 100 ng/mL to 300 ng/mL.<br />In addition to increasing myocardial contractility, milrinone improves diastolic function as evidenced by improvements in left ventricular diastolic relaxation.</p><p>The acute administration of intravenous milrinone has also been evaluated in clinical trials in excess of 1600 patients, with chronic heart failure, heart failure associated with cardiac surgery, and heart failure associated with myocardial infarction. The total number of deaths, either on therapy or shortly thereafter (24 hours) was 15, less than 0.9%, few of which were thought to be drug-related.</p><p>Clinical efficacy and safety<br />In patients with heart failure due to depressed myocardial function, milrinone produced a prompt dose and plasma concentration related increase in cardiac output and decreases in pulmonary capillary wedge pressure and vascular resistance, which were accompanied by mild-to-moderate increases in heart rate. Additionally, there is no increased effect on myocardial oxygen consumption.<br />In uncontrolled studies, haemodynamic improvement during intravenous therapy with milrinone was accompanied by clinical symptomatic improvement, but the ability of milrinone to relieve symptoms has not been evaluated in controlled clinical trials. The great majority of patients experience improvements in hemodynamic function within 5 to 15 minutes of initiation of therapy. In studies in congestive heart failure patients, milrinone when administered as a loading injection followed by a maintenance infusion produced significant mean initial increases in cardiac index of 25%, 38%, and 42% at dose regimens of 37.5 &mu;g/kg/0.375 &mu;g/kg/min, 50 &mu;g/kg/0.50 &mu;g/kg/min, and 75&mu;g/kg/0.75&mu;g/kg/min, respectively. Over the same range of loading injections and maintenance infusions, pulmonary capillary wedge pressure significantly decreased by 20%, 23%, and 36%, respectively, while systemic vascular resistance significantly decreased by 17%, 21%, and 37%. Mean arterial pressure fell by up to 5% at the two lower dose regimens, but by 17% at the highest dose. Patients evaluated for 48 hours- maintained improvements in hemodynamic function, with no evidence of diminished response (tachyphylaxis). A smaller number of patients have received infusions of milrinone for periods up to 72 hours without evidence of tachyphylaxis.<br />The duration of therapy should depend upon patient responsiveness.<br />Milrinone has a favourable inotropic effect in fully digitalized patients without causing signs of glycoside toxicity. Theoretically, in cases of atrial flutter/fibrillation, it is possible that milrinone may increase ventricular response rate because of its slight enhancement of AV-node conduction. In these cases, digitalis should be considered prior to the institution of therapy with milrinone. Improvement in left ventricular function in&nbsp;patients with ischemic heart disease has been observed. The improvement has occurred without inducing symptoms or electrocardiographic signs of myocardial ischemia. The steady-state plasma milrinone concentrations after approximately 6 to 12hours of unchanging maintenance infusion of 0.50&mu;g/kg/min are approximately 200 ng/mL. Near maximum favourable effects of milrinone on cardiac output and pulmonary capillary wedge pressure are seen at plasma milrinone concentrations in the 150 ng/mL to 250 ng/mL range.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following intravenous injections of 12.5 &mu;g/kg to 125 &mu;g/kg to congestive heart failure patients, milrinone had a volume of distribution of 0.38 litres/kg, a mean terminal elimination half-life of 2.3 hours, and a clearance of 0.13 litres/kg/hr. Following intravenous infusions of 0.20 &mu;g/kg/min to 0.70&mu;g/kg/min to congestive heart failure patients, the drug had a volume of distribution of about 0.45 litres/kg, a mean terminal elimination half-life of 2.4 hours, and a clearance of 0.14 litres/kg/hr. These pharmacokinetic parameters were not dose-dependent, and the area under the plasma concentration versus time curve following injections was significantly dose-dependent. Milrinone has been shown (by equilibrium dialysis) to be approximately 70% bound to human plasma protein.</p><p>The primary route of excretion of milrinone in man is via the urine. The major urinary excretions of orally administered milrinone in man are milrinone (83%) and its 0- glucuronide metabolite (12%). Elimination in normal subjects via the urine is rapid, with approximately 60% recovered within the first two hours following dosing and approximately 90% recovered within the first eight hours following dosing. The mean renal clearance of milrinone is approximately 0.3 litres/min, indicative of active secretion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pregnancy: Teratogenic Effects:</em></p><p>Pregnancy Category C Oral administration of milrinone to pregnant rats and rabbits during organogenesis produced no evidence of teratogenicity at dose levels up to 40 mg/kg/day and 12 mg/kg/day, respectively. Milrinone did not appear to be teratogenic when administered intravenously to pregnant rats at doses up to 3 mg/kg/day (about 2.5 times the maximum recommended clinical intravenous dose) or pregnant rabbits at doses up to 12 mg/kg/day, although an increased resorption rate was apparent at both 8 mg/kg/day and 12 mg/kg/day (intravenous) in the latter species.</p><p><em>Carcinogenesis, Mutagenesis, Impairment of Fertility</em></p><p>Twenty-four months of oral administration of milrinone to mice at doses up to 40 mg/kg/day (about 50 times the human oral therapeutic dose in a 50 kg patient) was&nbsp;unassociated with evidence of carcinogenic potential. Neither was there evidence of carcinogenic potential when milrinone was orally administered to rats at doses up to 5 mg/kg/day (about 6 times the human oral therapeutic dose) for twenty-four months or at 25 mg/kg/day (about 30 times the human oral therapeutic dose) for up to 18 months in males and 20 months in females. Whereas the Chinese Hamster Ovary Chromosome Aberration Assay was positive in the presence of a metabolic activation system, results from the Ames Test, the Mouse Lymphoma Assay, the Micronucleus Test, and the in vivo Rat Bone Marrow Metaphase Analysis indicated an absence of mutagenic potential. In reproductive performance studies in rats, milrinone had no effect on male or female fertility at oral doses up to 32 mg/kg/day</p><p><em>Animal Toxicity</em></p><p>Oral and intravenous administration of toxic dosages of milrinone to rats and dogs resulted in myocardial degeneration/fibrosis and endocardial haemorrhage, principally affecting the left ventricular papillary muscles. Coronary vascular lesions characterised by periarterial oedema and inflammation have been observed in dogs only. The myocardial/endocardial changes are similar to those produced by beta-adrenergic receptor agonists such as isoproterenol, while the vascular changes are similar to those produced by minoxidil and hydralazine. Doses within the recommended clinical dose range (up to 1.13 mg/kg/day) for congestive heart failure patients have not produced significant adverse effects in animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dextrose Anhydrous</p><p>Lactic Acid</p><p>Sodium Hydroxide</p><p>Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Furosemide or bumetanide should not be administered in intravenous lines containing Milrinone TBM since precipitation occurs on admixture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
Shelf life after dilution according to directions: On dilution with 0.9% Sodium chloride 
Injection or 5% Dextrose Injection USP is stable for a period of 72 hours at 2°C-8 ºC and 
24 hours at room temperature.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Do not store above 30&deg;C.&nbsp;Avoid freezing.</strong><br />For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Milrinone TBM is a clear and colourless to pale yellow solution containing 1 mg of Milrinone USP per mL.</p><p>The product is filled as 10 mg in 10 mL USP Type I clear glass vial, stoppered with 20 mm Bromobutyl rubber stoppers and sealed with 20 mm aluminium flip off seals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Instructions for use: For single use only.<br />Infusion solutions diluted as recommended with 0.9% Sodium Chloride Injection or 5% Dextrose Injection should be freshly prepared before use.<br />Parenteral drug products should be examined visually and should not be used if particulate matter or discolouration is present.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tadawi Biomedical Company 
Tadawi Biomedical - KSA 
Riyadh, Sudair Industrial 
Area, Zone A, Road 11, 
Factory 107 - Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                XXXX
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>